Cargando…

Recombinant human epoetin beta in the treatment of renal anemia

Cardiovascular disease is the leading cause of the poor long-term survival of patients with chronic kidney disease (CKD). Anemia complicating CKD not only impairs patients’ quality of life, but is also an independent risk factor for adverse cardiovascular outcomes. The availability of recombinant hu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locatelli, Francesco, Pozzoni, Pietro, Vecchio, Lucia Del
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386355/ https://www.ncbi.nlm.nih.gov/pubmed/18488073

Ejemplares similares

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
por: Macpherson, Iain RJ, et al.
Publicado: (2009)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
por: Galli, Luca, et al.
Publicado: (2015)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
por: Ohashi, Naro, et al.
Publicado: (2012)

Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
por: Beiraghdar, Fatemeh, et al.
Publicado: (2015)

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease
por: Aizawa, Ken, et al.
Publicado: (2018)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure
por: Jöbsis, Jasper J., et al.
Publicado: (2010)

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience
por: Kacarska - Fotevska, Isidora Isidora, et al.
Publicado: (2020)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience
por: Kacarska-Fotevska, Isidora, et al.
Publicado: (2019)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
por: Davis-Ajami, Mary Lynn, et al.
Publicado: (2014)

The resistance to methoxy polyethylene glycol-epoetin beta in anemic patients of end-stage renal disease
por: Abood, Sattar J., et al.
Publicado: (2023)

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
por: Carrera, Fernando, et al.
Publicado: (2010)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Topical ocular delivery of nanoparticles with epoetin beta in Wistar Hannover rats
por: Silva, Beatriz, et al.
Publicado: (2023)

Epoetin Delta Reduces Oxidative Stress in Primary Human Renal Tubular Cells
por: De Beuf, Annelies, et al.
Publicado: (2010)

Pure red cell aplasia after treatment of renal anaemia with epoetin theta
por: Herrington, W., et al.
Publicado: (2013)

Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery
por: Silva, Beatriz, et al.
Publicado: (2022)

Systemic and targeted steroids for the treatment of IgA nephropathy
por: Locatelli, Francesco, et al.
Publicado: (2023)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study
por: Patsialas, Stavros, et al.
Publicado: (2023)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
por: Irrera, Natasha, et al.
Publicado: (2015)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
por: Wish, Jay B., et al.
Publicado: (2019)

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
por: London, Gérard, et al.
Publicado: (2018)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
por: Hayashi, Terumasa, et al.
Publicado: (2018)

Biosimilar Retacrit(®) (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study
por: Losem, Christoph, et al.
Publicado: (2017)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis
por: Aapro, M, et al.
Publicado: (2006)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
por: Casadevall, Nicole, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_snr9819nl7395ehqhmtn06eis7